Nigella Sativa reduces COVID-19 risk: real-time meta-analysis of 15 studies (Version 24)

Covid Analysis, Nov 2026

Nigella Sativa for COVID-19

12th treatment shown to reduce risk in January 2021, now with p = 0.00003 from 15 studies.

No treatment is 100% effective.
Protocols combine treatments.

Significantly lower risk is seen for ventilation, hospitalization, progression, recovery, cases, and viral clearance. 12 studies from 11 independent teams in 9 countries show significant benefit.
Meta-analysis using the most serious outcome reported shows 44% [27‑57%] lower risk. Results are similar for Randomized Controlled Trials, higher quality studies, and peer-reviewed studies. Early treatment is more effective than late treatment.
Results are very robust—in worst case exclusion sensitivity analysis 12 of 15 studies must be excluded before statistical significance is lost. Emergent results for early vs. late treatment (p = 0.034) that match biological mechanisms confirm efficacy.
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Dietary sources may be preferred. The quality of non-prescription supplements varies widely1-3. A lipid-optimized formulation may be required for therapeutic concentrations of nigella sativa, and may aid distribution to target tissues. All data and sources to reproduce this analysis are in the appendix.
Other meta-analyses show significant improvements with nigella sativa for mortality4-6, progression6, and viral clearance5.
3 meta-analyses show significant improvements with nigella sativa for mortality1-3, progression3, and viral clearance2.
Covid Analysis et al., Nov 2026, preprint, 1 author.